Evaluation of MDR1 expression and FLT3-ITD mutations in AML patients is important, and it has been shown that patients with both FLT3-ITD mutations and MDR1 overexpression have poorer overall survival (6). The gene discussed is FLT3; the disease is acute myeloid leukemia.